VIVA 23: DETOUR 1 and DETOUR2: PQ Bypass System for Percutaneous Femoropopliteal Bypass

Published: 22 Nov 2023

  • Views:

    Views Icon 84
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

VIVA 23 - We are joined virtually by Dr Sean Lyden (Cleveland Clinic, US) to discuss the findings of a pooled analysis of the DETOUR1 and DETOUR2 studies, which clinically investigated a device intended to improve blood flow in patients with peripheral arterial disease due to femoropopliteal chronic total occlusions.

Results suggest that at 2 years, the PQ bypass system is a safe and effective percutaneous treatment option for patients with longer, severely calcified lesions.

Interview Questions:

  1. What are the unmet needs for PAD patients with symptomatic femoropoliteal chronic total occlusions?
  2. Could you tell us about the unique features of the PQ Bypass System?
  3. What was the study design and patient population?
  4. What were the key results?
  5. What are your take-home messages?
  6. What further study is needed?

Recorded remotely from Ohio, 2023.

Editor: Jordan Rance
Video Specialist: Oliver Miles


You must be to comment. If you are not registered, you can register here.